SCHEMBL397989

SCHEMBL397989

CCOC(=O)c1cc(Br)c(OCOC)c(C(=O)OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TSHR P16473 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
ESR1 P03372 1/20 0.39
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 2/20 0.37
P2RY12 Q9H244 1/20 0.37
HSD17B2 P37059 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403025 0.90 ALDH1A1 (0.40) MAPTL3MBTL1TSHRCA12CA1
SCHEMBL403026 0.90 HSD17B10 (0.42) MAPTL3MBTL1TSHRCA12CA1
SCHEMBL5989845 0.89 CA12 (0.49) MAPTL3MBTL1TSHRCA12CA1
SCHEMBL5991186 0.83 CA12 (0.43) MAPTL3MBTL1TSHRCA12CA1
SCHEMBL30940291 0.82 XDH (0.41) MAPTKMT2AKDM4EALDH1A1
SCHEMBL401407 0.79 ESR1 (0.54) MAPTL3MBTL1TSHRCA12CA1
SCHEMBL403251 0.75 NOTUM (0.42) MAPTL3MBTL1TSHRCA12CA1
SCHEMBL10205503 0.75 SMN1; SMN2 (0.53) MAPTL3MBTL1TSHRKMT2ALMNA
SCHEMBL21817206 0.75 THRB (0.46) MAPTL3MBTL1TSHRKMT2ALMNA
SCHEMBL22750310 0.74 NOTUM (0.38) MAPTL3MBTL1TSHRCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
CN-101056628-B Ester derivatives and medicinal use thereof JAPAN TOBACCO INC 2011-05-25 CN disclosed
CN-101056628-A Ester derivatives and medicinal use thereof JAPAN TOBACCO INC (JP) 2007-10-17 CN disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA MAPT 3451/4885L3MBTL1 2023/4885TSHR 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.